MedTrace Logo

FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer

NCT00578201 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-03-31

No results posted yet for this study

Summary

This phase II trial is studying the effects of oxaliplatin, leucovorin and fluorouracil-when given together with Cetuximab and radiation therapy and radiation therapy to see how they work in treating patients with stage III esophageal cancer.

Conditions

  • Esophageal Cancer Stage III

Interventions

DRUG

radiochemotherapy,combination Cetuximab-FOLFOX

objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX

Sponsors & Collaborators

  • GERCOR - Multidisciplinary Oncology Cooperative Group

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Gérard LLEDO, MD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578201 on ClinicalTrials.gov